The pan-cancer IncRNA MILIP links c-Myc to p53 repression

Yu Chen Feng a, Xiao Hong Zhao a, Liu Teng b, Rick F. Thorne a, b, Lei Jin b, c, and Xu Dong Zhang a, b

a School of Biomedical Sciences and Pharmacy, The University of Newcastle, Callaghan, Australia; b Translational Research Institute, Henan Provincial People’s Hospital and People’s Hospital of Zhengzhou University, Academy of Medical Science, Zhengzhou University, Henan, China; c School of Medicine and Public Health, The University of Newcastle, Callaghan, Australia

ABSTRACT

We have recently identified the MYC proto-oncogene, bHLH transcription factor (MYC, best known as c-Myc)-responsive pan-cancer IncRNA c-Myc-Inducible Long noncoding RNA Inactivating P53 (MILIP) as an oncogenic driver. Our studies show that MILIP facilitates tumor protein p53 (TP53, best known as p53) turnover by reducing its SUMOylation through suppressing tripartite-motif family-like 2 (TRIML2), thus promoting cell survival, proliferation, and tumorigenicity. MILIP may thus represent an anti-cancer target for counteracting the c-Myc axis.

The proto-oncoprotein MYC proto-oncogene, bHLH transcription factor (MYC, best known as c-Myc) and the tumor suppressor tumor protein p53 (TP53, best known as p53) are inextricably linked as “Yin and Yang” partners in normal cells to maintain tissue homeostasis. However, the regulatory interactions are not retained by cancer cells as evidenced by the often-imbalanced expression of c-Myc over wildtype p53. Although p53 repression is frequently associated with the loss of cyclin-dependent kinase inhibitor 2A (CDKN2A, best known as ARF) tumor suppressor (p14ARF in human and p19ARF in mouse), Feng et al. have recently reported an alternate mechanism whereby c-Myc inactivates p53 through the c-Myc-Inducible Long noncoding RNA (lncRNA) Inactivating P53 (MILIP) in the pancancer context, uncovering an axis inhibiting p53 through a pan-cancer expressed lncRNA accomplice that links c-Myc to repression of p53.

Inspired by the findings that MILIP is one of the most upregulated lncRNA in 18 of 20 cancer types in relation to corresponding normal tissues in the Cancer Genome Atlas (TCGA) and that MILIP is transcriptionally activated by c-Myc, Feng et al. set to investigate its potential role in cancer pathogenesis. After confirming the upregulation of MILIP in independent cohorts of non-small cell lung carcinoma and colon cancer tissues, they conducted RNA-sequencing analysis and found that p53 signaling was the most enriched gene pathway resulting from MILIP silencing. In support, the p53 protein itself was upregulated when MILIP was silenced. Conversely, MILIP overexpression caused reduction in p53 expression. These results, along with the finding that c-Myc transcriptionally activates MILIP, suggest that, in contrast to upregulating p53 in normal cells, c-Myc may inactivate p53 through MILIP in cancer cells. Indeed, c-Myc silencing upregulated p53, which was nevertheless abolished by MILIP overexpression. In contrast, c-Myc overexpression caused downregulation of p53 that was diminished by MILIP silencing. Thus, MILIP links c-Myc to inactivating p53.

Feng et al. then investigated the functional significance of MILIP. MILIP silencing retarded the tumorigenicity of A549 and MCF-7 cells in vitro and in A549 cancer xenograft models, whereas MILIP overexpression promoted clonogenicity of A549 and MCF-7 cells. As anticipated, MILIP silencing triggered apoptosis and cell cycle arrest at G0/G1 phase, functional characteristics of p53 activation. In accord, co-silencing of p53 reversed the inhibitory effect of MILIP silencing on clonogenicity, consolidating that MILIP expression is integral for sustaining cancer cell survival and division through repressing p53. Similar to c-Myc, high MILIP expression was associated with poor overall survival in various cancer types, supporting the notion that MILIP upregulation contributes to c-Myc-driven cancer maintenance and progression. Importantly, although MILIP silencing did not influence the viability of normal human mammary epithelial cells, it decelerated anchorage-independent growth of normal cells caused by c-Myc overexpression in conjunction with knockdown of p14ARF. In contrast, MILIP overexpression promoted the anchorage-independent growth of normal cells. Therefore, MILIP upregulation contributes to c-Myc-driven neoplastic transformation. In support, MILIP expression was increased in pre-neoplastic lesions (adenomas) compared with normal epithelia.

How does MILIP repress p53 expression? Feng et al. found that the increase in p53 protein expression caused by MILIP silencing was due to its prolonged half-life time. Although this was associated with reduction in p53 polyubiquitination, there were no significant alterations in the association between p53 and MDM2 proto-oncogene (MDM2), the major ubiquitin E3 ligase responsible for p53 ubiquitination. Strikingly, MILIP appeared to be an RNA binding partner of p53 and a MILIP...
mutant with the segment required for its binding to p53 deleted did not regulate p53 expression, suggesting that the direct interaction between MILIP and p53 is required for MILIP-mediated p53 repression.

To further understand the mechanism responsible for MILIP-mediated repression of p53, Feng et al. identified tripartite motif family like 2 (TRIML2) was one of the most upregulated genes encoding proteins that interact with p53.\(^8\) Silencing of TRIML2 reduced p53 protein levels, proposing that TRIML2 may be involved in the regulation of p53 by MILIP. Consistent with its role as a SUMO E3 ligase,\(^8\) TRIML2 bound to and modified p53 with SUMO-2/3. Nevertheless, TRIML2-mediated p53 SUMOylation was diminished by MILIP overexpression, whereas MILIP silencing increased modification of p53 by SUMO-2/3, which was counteracted by co-silencing of TRIML2. Therefore, MILIP negatively regulates p53 SUMOylation through suppressing TRIML2. Mechanistically, MILIP competes with TRIML2 for binding to p53. This was demonstrated by the findings that MILIP overexpression reduced the association between TRIML2 and p53, and in contrast, MILIP silencing increased the amount of TRIML2 co-immunoprecipitated with p53. On the other hand, TRIML2 overexpression reduced the amount of MILIP associating with p53, whereas its silencing increased binding of MILIP to p53.

In summary, Feng et al. have demonstrated that the pan-cancer lncRNA MILIP links c-Myc to repression of p53. As a proto-oncoprotein, c-Myc is cast as an enigmatic actor, playing dualistic roles as both villain and hero. For the latter, c-Myc triggers activation of p53 through ARF, which serves as a key checkpoint to curb malignant transformation through induction of apoptosis.\(^5\) Feng et al. establish that c-Myc inactivates p53 through MILIP,\(^4\) providing an explanation as to how wild-type p53 can be repressed by c-Myc independently of the loss of ARF. Noticeably, p14\(^{ARF}\) mRNA but not MILIP levels correlate with MYC gene expression in normal human tissues,\(^9\) whereas Feng et al. found that MILIP is upregulated and its expression is positively associated with the levels of MYC expression in human cancers. Thus, it is conceivable that transcriptional activation of MILIP requires

---

**Figure 1.** Molecular mechanisms underlying the differential impact of MYC proto-oncogene, bHLH transcription factor (MYC, best known as c-Myc) signaling on tumor protein p53 (TP53, best known as p53) expression in normal and cancer cells. In normal cells, physiological (relatively low) levels of c-Myc is sufficient for transcriptional activation of cyclin-dependent kinase inhibitor 2A (CDKN2A, best known as ARF) tumor suppressor that binds to and inhibits MDM2 proto-oncogene (MDM2), the major ubiquitin E3 ligase responsible for p53 polyubiquitination and degradation, leading to p53 activation. In contrast, oncogenic (relatively high) levels of c-Myc in cancer cells transcriptionally activates c-Myc-Inducible Long noncoding RNA (lncRNA) Inactivating P53 (MILIP), which compete with tripartite motif family like 2 (TRIML2) for binding to p53 resulting in decreases in p53 SUMOylation and occurrent increases in its polyubiquitination and subsequent proteosomal degradation.
oncogenic (relatively high) levels of c-Myc, whereas physiological (relatively low) levels of c-Myc are sufficient for transcriptional activation of p14ARF (Figure 1).10

Abbreviations

- c-Myc: MYC proto-oncogene, bHLH transcription factor (MYC, best known as c-Myc)
- p53: Tumor protein p53 (TP53, best known as p53)
- ARF: Cyclin dependent kinase inhibitor 2A (CDKN2A, best known as ARF)
- lncRNA: Long noncoding RNA
- MILIP: c-Myc-Inducible Long noncoding RNA Inactivating P53
- TCGA: The Cancer Genome Atlas
- MDM2: MDM2 proto-oncogene
- TRIML2: Tripartite motif family like 2

Disclosure of potential conflicts of interest

No potential conflicts of interest were disclosed.

Funding

This work was supported by the National Health and Medical Research Council (NHMRC) under Grants APP1147271, APP1162753, APP1177087; and Cancer Council NSW under Grant RG20-01

ORCID

Yu Chen Feng  
Rick F. Thorne

References

1. Sachdeva M, Mo YY. p53 and c-myc: how does the cell balance "yin" and "yang"? Cell Cycle. 2009;8(9):1303. doi:10.4161/cc.8.9.8362.
2. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature. 2001;411(6835):342–348. doi:10.1038/35077213.
3. Kim WY, Sharpless NE. The regulation of INK4/ARF in cancer and aging. Cell. 2006;127(2):265–275. doi:10.1016/j.cell.2006.10.003.
4. Feng YC, Liu XY, Teng L, Ji Q, Wu Y, Li JM, Gao W, Zhang YY, La T, Tabatabaee H, et al. c-Myc inactivation of p53 through the pan-cancer lncRNA MILIP drives cancer pathogenesis. Nat Commun. 2020;11(1):4980. doi:10.1038/s41467-020-18735-8.
5. Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, Sherr CJ, Roussel MF. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 1998;12(15):2424–2433. doi:10.1101/gad.12.15.2424.
6. Kastenhuber ER, Lowe SW. Putting p53 in context. Cell. 2017;170 (6):1062–1078. doi:10.1016/j.cell.2017.08.028.
7. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature. 1997;387(6630):299–303. doi:10.1038/387299a0.
8. Kung CP, Khaku S, Jennis M, Zhou Y, Murphy ME. Identification of TRIML2, a novel p53 target, that enhances p53 SUMOylation and regulates the transactivation of proapoptotic genes. Mol Cancer Res. 2015;13(2):250–262. doi:10.1158/1541-7786.MCR-14-0385.
9. Taten C, Miya F, Wake K, Kataoka M, Ishida Y, Yamasaki C, Yanagi A, Kakuni M, Wisse E, Verheyen F, et al. Morphological and microarray analyses of human hepatocytes from xenogeneic host livers. Lab Invest. 2013;93(1):54–71. doi:10.1038/ lainvest.2012.158.
10. Murphy DJ, Junttila MR, Pouyet L, Karnezis A, Shchors K, Bui DA, Brown-Swigart L, Johnson L, Evan GI. Distinct thresholds govern Myc’s biological output in vivo. Cancer Cell. 2008;14(6):447–457. doi:10.1016/j.ccr.2008.10.018.